Nasdaq
$0.9800▲ 3.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.2MShares out 12.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
1- 7.30Pre-market26.07.30 20:308-KKey event#●●●#●●●
Tvardi Therapeutics, Inc.Bullish
Tvardi Therapeutics는 차세대 STAT3 억제제인 TTI-109의 첫 번째 적응증으로 궤양성 대장염(UC)을 확정했습니다. 회사는 건강한 지원자를 대상으로 한 임상 1상에서 TTI-109가 UC 병리에 관여하는 Th17, Tfh, B세포 등 면역 세포군을 유의미하게 조절함을 확인했으며, 2027년 중등도-중증 UC 환자를 대상으로 임상 시험을 개시할 계획입니다.…more
$0.9800+3.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
News
GlobeNewswire- 10.14Pre-market26.10.14 21:00#●●●#●●●
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference…more
Tvardi Therapeutics announced that its management will present at Chardan’s 10th Annual Healthcare Conference. The event serves as an opportunity for investor engagement regarding the company's clinical progress, with no new financial or contractual milestones announced.…more
$0.9800+3.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.24Pre-market26.09.24 21:04
●●●●●●●● ●●●●● ●●●●●●
Tvardi Therapeutics announced the publication of preclinical data for its STAT3 inhibitor, TTI-101, in the International Journal of Molecular Sciences. The study demonstrates the drug's ability to modulate disease biology in colitis and colorectal cancer models, supporting the development of its next-generation therapy.…more
$0.9800+3.47%vs prev closeShareBenzinga - 8.26Pre-market26.08.26 21:00
●●●●●●●● ●●●●● ●●●●●●
Tvardi Therapeutics announced that management will participate in three major healthcare investor conferences throughout September. These events consist of company presentations and investor meetings, with no new material clinical or financial data disclosed.…more
$0.9800+3.47%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report